Lymphoma News and Research

RSS

Lymphoma is cancer that begins in cells of the immune system. There are two basic categories of lymphomas. One kind is Hodgkin lymphoma, which is marked by the presence of a type of cell called the Reed-Sternberg cell. The other category is non-Hodgkin lymphomas, which includes a large, diverse group of cancers of immune system cells. Non-Hodgkin lymphomas can be further divided into cancers that have an indolent (slow-growing) course and those that have an aggressive (fast-growing) course. These subtypes behave and respond to treatment differently. Both Hodgkin and non-Hodgkin lymphomas can occur in children and adults, and prognosis and treatment depend on the stage and the type of cancer.

California cracks down on weed killer as lawsuits abound

Jack McCall was a fixture at the local farmers market, where he sold avocados and other fruits he grew on his 20-acre ranch in Cambria, on California's Central Coast.

8 Nov 2017

Adipocytes may reduce effectiveness of chemotherapeutic drug

Adipocytes, or fat cells, can absorb and metabolize the chemotherapeutic agent daunorubicin, reducing the effectiveness of the drug and potentially contributing to poorer treatment outcomes.

8 Nov 2017

New category of immunotherapy appears safe to use in patients with both cancer and HIV

A new category of immunotherapies called checkpoint inhibitors that has been highly effective against many different cancers appears safe to use in patients with both advanced malignancies and HIV, a population excluded from earlier trials of such therapies, according to an early-phase trial.

7 Nov 2017

FDA grants accelerated approval to new treatment for mantle cell lymphoma

The U.S. Food and Drug Administration today granted accelerated approval to Calquence (acalabrutinib) for the treatment of adults with mantle cell lymphoma who have received at least one prior therapy.

1 Nov 2017

VICC selected to administer FDA-approved CAR T therapy for treatment of lymphoma patients

Vanderbilt-Ingram Cancer Center has been selected as one of the few authorized treatment centers in the United States approved to administer the first FDA- approved chimeric antigen receptor T cell (CAR T) therapy for treatment of adult patients with a specific type of lymphoma.

25 Oct 2017

Researchers develop new way to genetically engineer T cells for treating leukemia relapse

Researchers at Fred Hutchinson Cancer Research Center and the University of Washington have developed a novel way to genetically engineer T cells that may be effective for treating and preventing leukemia relapse.

25 Oct 2017

Penn researchers provide new insights into how Notch drives growth of B-cell cancers

Notch is one of the most frequently mutated genes in chronic lymphocytic leukemia (CLL), the most common leukemia in adults in the United States. It is also often mutated in other common B cell tumors, such as mantle cell lymphoma.

23 Oct 2017

Dana-Farber, Brigham and Women's Cancer Center certified to offer new CAR T-cell therapy

Following a successful clinical trial involving Dana-Farber Cancer Institute and Brigham and Women's Hospital, the first chimeric antigen receptor (CAR) T-cell therapy for adult cancers was approved by the Food and Drug Administration today.

20 Oct 2017

Amid for-profit surge, rural hospice has offered free care for 40 years

Rose Crumb can't even count the number of people she's helped die. The former nurse, 91, who retired in her mid-80s, considers the question and then shakes her head, her blue eyes sharp above oval spectacles.

20 Oct 2017

New CAR-T cell therapy offers effective option for certain blood cancer patients

Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis is one of the first centers nationwide to offer a new immunotherapy that targets certain blood cancers.

19 Oct 2017

Novel gene expression signature assay could help enhance lymphoma management

Diffuse large B-cell lymphoma (DLBCL) is an aggressive cancer and the most frequently diagnosed non-Hodgkin lymphoma worldwide (nearly 40% of cases). Recent advancements indicate that both the prognosis and choice of treatment of DLBCL may depend on identifying its molecular subtype.

17 Oct 2017

Study provides detailed characterization of neurotoxicity arising from CD19 CAR T-cell therapy

New potential biomarkers and a novel algorithm could help identify patients at increased risk of suffering from severe neurotoxicity after receiving CD19 CAR T-cell therapy. The study extensively characterized common and occasionally fatal side effects of this immunotherapy.

12 Oct 2017

Existing drugs could help patients with rare form of bone cancer

Patients with a rare bone cancer of the skull and spine - chordoma - could be helped by existing drugs, suggest scientists from the Wellcome Trust Sanger Institute, University College London Cancer Institute and the Royal National Orthopaedic Hospital NHS Trust.

12 Oct 2017

Researchers pinpoint genetic drivers of diffuse large B cell lymphoma

Lymphoma is the most common blood cancer, but the diagnosis belies a wildly diverse and little understood genetic foundation for the disease that hampers successful treatment.

5 Oct 2017

Study on cell stress response may hold promise for treating inflammation-related disorders

Stress – defined broadly – can have a profoundly deleterious effect on the human body. Even individual cells have their own way of dealing with environmental strains such as ultraviolet radiation from the sun or germs.

4 Oct 2017

Tattoo ink from 15 years ago mimics lymph node cancer: Case study

A 30 year old Australian woman presented to the doctors with numerous small lumps under her arms for around two weeks. When one of the nodes were put under the microscope, the doctors found pigments from tattoo ink that she’d got 15 years back.

4 Oct 2017

Plant extracts may help protect against negative effects of X-ray irradiation

A compound found in coriander and ginger may help protect against the negative effects of radiation exposure.

3 Oct 2017

First-ever treatment for Merkel cell carcinoma receives approval in Japan

Merck KGaA, Darmstadt, Germany, and Pfizer Inc. today announced that the Japanese Ministry of Health, Labor, and Welfare (MHLW) has approved BAVENCIO (avelumab, genetically recombinant Injection 200mg/mL for intravenous use) as the first and only treatment indicated for curatively unresectable Merkel cell carcinoma (MCC), a rare and aggressive cancer, in Japan.

27 Sep 2017

Trial identifies genetic fault that affects treatment response in leukemia patients

A genetic fault has been identified in people with an aggressive type of leukemia that can significantly affect how they respond to treatment.